Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alfa Financial Software delivers 'strong' Q1 trading performance

(Sharecast News) - Software developer Alfa Financial Software said on Tuesday that it had delivered a "strong trading performance" in the three months ended 31 March, with total contract values reaching a new record in the quarter. Alfa Financial said Q1 revenues had grown 20% year-on-year to £31.0m, with subscription revenues up 21% on Q124, while software engineering revenues grew 79% and delivery revenues improved 8%.

The FTSE 250-listed group highlighted that total contract values at the end of the quarter were at an all-time high of £227.0m, up from the previous record of £221.0m on 31 December 2024 and versus £190.0m at the same time a year earlier.

Chief executive Andrew Denton said: "We've had a strong start to the year across all revenue streams as we deliver for new customers, upgrade existing customers to Alfa Systems 6 and work with late-stage prospects through the sales process. We continue to see fantastic sequential growth in our Subscription revenues, up 6% on last quarter and 21% on the same quarter last year.

"We continue to invest in the product and our people to further enhance our leading position in the market and our excellent delivery track record. We have seen no change in customer buying behaviour as a result of current macro-economic uncertainty and we are well positioned to achieve our expectations for the year."

As of 0905 BST, Alfa Financial shares were up 1.39% at 219.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.